ReviewThrombosis research2021
COVID-19 and thrombotic microangiopathies.
Review in Thrombosis research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 93 citations in OpenAlex.
- IPNA clinical practice recommendations for the management of aHUS and secondary TMA in children.Pediatric nephrology (Berlin, Germany) · 2026Article
- Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient.Frontiers in medicine · 2026Article
- Single-pixel imaging flow cytometry for biomedical research.Inflammation and regeneration · 2025Review
- SARS-CoV-2 enhances complement-mediated endothelial injury via the suppression of membrane complement regulatory proteins.Emerging microbes & infections · 2025Article
- The Role of Toll-like Receptors and Viral Infections in the Pathogenesis and Progression of Pulmonary Arterial Hypertension-A Narrative Review.International journal of molecular sciences · 2025Review
- The impact of the COVID-19 pandemic on incidence and clinical presentation of thrombotic microangiopathies: data from a laboratory centralizing ADAMTS-13 testing in Quebec.Orphanet journal of rare diseases · 2025Article
- COVID-19-induced thrombotic microangiopathy in patients with multiple myeloma receiving carfilzomib treatment.International journal of hematology · 2025Article
- Thrombotic microangiopathy with irreversible renal function in a CKD patient following COVID-19: case report.Frontiers in medicine · 2025Article
- Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: A Single-Center Experience.International journal of molecular sciences · 2024Article
- Long-term clinicopathological characteristics of TAFRO syndrome and its relapse: a case series study.Clinical kidney journal · 2024Article
- Article
- Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection.Life (Basel, Switzerland) · 2024Article
- COVID-19 and Antipsychotic Therapy: Unraveling the Thrombosis Risk.International journal of molecular sciences · 2024Review
- Thrombocytopenia Secondary to COVID-19: Outcomes Analysis in Terms of Thrombotic Microangiopathy, Acute Kidney Injury, and Mortality.International journal of hematology-oncology and stem cell research · 2024Article
- Pathomorphological Features of the Novel Coronavirus Disease in Patients with Systemic Amyloidosis.Biomedicines · 2023Article
- Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios.Journal of translational medicine · 2023Article
- eGFRBMC nephrology · 2023Article
- Thrombosis in Multisystem Inflammatory Syndrome Associated with COVID-19 in Children: Retrospective Cohort Study Analysis and Review of the Literature.Biomedicines · 2023Article
- Acute and chronic histopathological findings in renal biopsies in COVID-19.Clinical and experimental medicine · 2023Review
- SARS-CoV-2 Infection and Preeclampsia-How an Infection Can Help Us to Know More about an Obstetric Condition.Viruses · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe COVID-19 can manifest as multiorgan dysfunction with pulmonary involvement being the most common and prominent. As more reports emerge in the literature, it appears that an exaggerated immune response in the form of unfettered complement activation and a cytokine storm may be a key driver of the widespread organ injury seen in this disease. In addition, these patients are also known to be hypercoagulable with a high rate of thrombosis and a higher-than-expected failure rate of anticoagulation. While macrovascular thrombosis is common in these individuals, the frequent finding of extensive microvascular thromboses in several series and case reports, raises the possibility of thrombotic microangiopathy (TMA) as being a contributing factor in the thrombotic and multi-organ complications of the disease. If this is correct, rapidly identifying a TMA and treating the underlying pathophysiology may allow for better outcomes in these critically ill patients. To further explore this, we reviewed the published literature on COVID-19, looking for reports describing TMA-like presentations. We summarize our findings here along with a discussion about presentation, pathophysiology, and a suggested treatment algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.